Result for
Tag: vaccine
April 23, 2021
Real World Effectiveness of COVID-19 mRNA Vaccines against Hospitalizations and Deaths in the United States
[Pre-print, not peer-reviewed] A large, retrospective cohort analysis of patients enrolled in a Houston, TX healthcare network (N=91,134) found that vaccination with 2 doses of either the Pfizer-BioNTech or Moderna vaccine reduced the risk of COVID-19 hospitalization by 96% and COVID-19 associated deaths by 99%. Additionally, the study found that persons with partial immunization, (defined…
April 21, 2021
A Real World Evaluation of the Safety and Immunogenicity of the Covishield Vaccine ChAdOx1 NCoV- 19 Corona Virus Vaccine (Recombinant) in Health Care Workers (HCW) in National Capital Region (NCR) of India A Preliminary Report
[Pre-print, not peer-reviewed] A real-world study of the safety and immunogenicity of one dose of the Covishield (Oxford-AstraZeneca) vaccine among healthcare workers in India (n = 1,638) found that 79.0% were seropositive 2 weeks after the 1st dose, an increase from the 48.2% who were seropositive at baseline. Among those with prior infection, 98.2% were…
April 19, 2021
Efficacy of the BNT162b2 MRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia
Among patients with chronic lymphocytic leukemia (CLL, n = 169) who received two doses of the Pfizer-BioNTech vaccine, the antibody response rate was 39.5% as measured by the Elecsys Anti-SARS-CoV-2 assay at a median of 15 days after the second dose. Compared to age- and sex-matched controls, the response rate among patients with CLL was…
Reduced Humoral Response to MRNA SARS‐Cov‐2 BNT162b2 Vaccine in Kidney Transplant Recipients without Prior Exposure to the Virus
Few kidney transplant recipients (51/136, 38.5%) who had been fully vaccinated with the Pfizer-BioNTech vaccine developed a positive response to the SARS-CoV-2 spike protein, suggesting that this population may remain at risk of infection despite vaccination. Compared to controls, mean IgG anti‐spike levels were lower (31.05 vs 200.5 AU/mL). Older age (OR = 1.7), use…
April 16, 2021
Distinct Antibody and Memory B Cell Responses in SARS-CoV-2 Naïve and Recovered Individuals Following mRNA Vaccination
A single dose of an mRNA vaccine (Moderna or Pfizer-BioNTech) administered to SARS-CoV-2 naïve individuals produced neutralizing activity against the D614G variant in 50% of recipients and against the B.1.351 variant in 16% of recipients (n=33). Neutralizing activity improved to 100% against the D614G variant and 96% against the against the B.1.351 variant following a…
Spike Antibody Levels of Nursing Home Residents With or Without Prior COVID-19 3 Weeks After a Single BNT162b2 Vaccine Dose
Nursing home residents with a past history of COVID-19 were far more likely than those without a history of COVID-19 to mount an antibody response to the first dose of the Pfizer-BioNTech vaccine. Among a cohort of nursing home residents in France, all 36 residents with prior COVID-19 were seropositive for anti-spike (S) IgG antibodies…
April 14, 2021
Detection of SARS-CoV-2 Specific IgA in the Human Milk of COVID-19 Vaccinated Lactating Health Care Workers
[Pre-print, not peer-reviewed] SARS-CoV-2 specific IgA and IgG were detected in milk and plasma samples from 22 lactating healthcare workers who had received either the Moderna or Pfizer-BioNTech vaccines, with peak levels occurring 7-10 days after the second dose. Samples were collected prior to vaccination, after the first dose, and after the second dose in…
Adverse Events in Healthcare Workers after the First Dose of ChAdOx1 NCoV-19 or BNT162b2 MRNA COVID-19 Vaccination: A Single Center Experience
A study of 1st dose post-vaccination adverse events in Korean healthcare workers at a single hospital (N=1,483) found that adverse events were significantly more common in recipients of the Oxford/AstraZeneca vaccine (N=1,403) than the Pfizer-BioNTech vaccine (N=80). The adverse events included injection-site pain (78% vs. 51%), myalgia (61% vs. 11%), fatigue (52% vs. 8%), headache…
SARS-CoV-2 Spike E484K Mutation Reduces Antibody Neutralisation
An in-vitro study of serum from persons with either prior SARS-CoV-2 infection or two doses of the Pfizer-BioNTech vaccine (N=34) found that antibody neutralization in all samples was reduced against SARS-CoV-2 virus with a single spike E484K mutation compared to the USA-WA1/2020 strain (the strain first detected in the US). The largest reductions in antibody…
April 12, 2021
Antibody Responses in Elderly Residential Care Persons Following COVID-19 MRNA Vaccination
[Pre-print, not peer-reviewed] While all fully vaccinated long-term care residents (n = 70) in a cross-sectional study in the Pittsburg region between March 15 and April 1, 2021 had detectable SARS-CoV-2 antibodies, levels tended to be lower among those who were male, older, used steroid medications, or had a longer length of time since vaccination….
Previous page Next page